Aquisição de Avelumab 20 mg/ml fr. 10 ml, Abatacept 250 mg pó conc sol inj fr IV, Alemtuzumab 10 mg/ml sol inj fr 1.2 ml IV, Baricitinib 4 mg comp e Cetuximab 5 mg/ml sol inj fr 20 ml IV